Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases

Journal of Nuclear Medicine

Volumn 56, Issue 10, 2015, Pages 1513-1519

  Thapa, Pradeep ^a   Nikam, Dilip ^b   Das, Tapas ^c   Sonawane, Geeta ^a   Agarwal, Jai Prakash ^a   Basu, Sandip ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Cama Albless Hospital   (India)

^c BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

153Sm EDTMP; 177Lu EDTMP; Bone alkaline phosphatase (BAP); Bone pain palliation; Skeletal metastases

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; LEXIDRONAM SAMARIUM SM 153; LUTETIUM ETHYLENE DIAMINE TETRAMETHYLENE PHOSPHONATE LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE; LUTETIUM ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE;

ADULT; AGED; ANALGESIA; ANEMIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; LEUKOPENIA; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; THROMBOCYTOPENIA; TUMOR FLARE; BONE; BONE NEOPLASMS; COMPARATIVE STUDY; COMPLICATION; ENZYMOLOGY; KARNOFSKY PERFORMANCE STATUS; METABOLISM; METASTASIS; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SAFETY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; BONE NEOPLASMS; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SAFETY;

EID: 84943146969     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.155762     Document Type: Article

References (31)

1. Galasko CS. Diagnosis of skeletal metastases and response to treatment. Clin Orthop. 1995;312:64-75.
2. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509-524.
3. 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun. 2007;28:245-250.
4. Tripathi M, Singhal T, Chandrasekhar N, et al. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metas-tases. Indian J Cancer. 2006;43:86-92.
5. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer. 2000;88(suppl):3033-3037.
6. Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev. 2003;29:321-327.
7. Dolezal J, Vizda J, Odrazka K. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Urol Int. 2007;78:50-57.
8. Hoskin PJ. Radiotherapy for bone pain. Pain. 1995;63:137-139.
9. Dearnaley DP, Bayly RJ, A'Hern RP, et al. Palliation of bone metastases in prostate cancer: hemibody irradiation or strontium-89? Clin Oncol (R Coll Radiol). 1992;4:101-107.
10. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys. 1994;30:1187-1194.
11. McEwan AJ. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med. 1997;27:165-182.
12. Serafini AN. Therapy of metastatic bone pain. J Nucl Med. 2001;42:895-906.
13. Sola G, Arguelles MG, Botazzini DL, et al. Lutetium-177-EDTMP for bone pain palliation: preparation, biodistribution and pre-clinical studies. Radiochim Acta. 2000;88:157-161.
14. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm. 2008;23: 202-213.
15. 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med. 2013;38:88-92.
16. Bodei L, Lam M, Chiesa C, et al; European Association of Nuclear Medicine (EANM). EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008;35:1934-1940.
17. Lass P. Radionuclide treatment of bone metastases: current concepts and trends. Nucl Med Rev Cent East Eur. 2001;4:1-3.
18. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systemic review. Lancet Oncol. 2005;6:392-400.
19. McEwan AJ. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000;10:103-114.
20. 177Lu-labeled cyclic polyaminophospho-nates as potential agents for bone pain palliation. Appl Radiat Isot. 2002;57: 177-184.
21. Chakraborty S, Das T, Unni PR, et al. Lu-177 labelled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun. 2002;23: 67-74.
22. Ando A, Ando I, Tonami N, et al. Lu-177-EDTMP: a potential therapeutic bone agent. Nucl Med Commun. 1998;19:587-591.
23. 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging. 2015;42:79-88.
24. 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-1591.
25. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
26. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26:2-7.
27. 153Sm-EDTMP in patients with painful bone metastases of breast cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003;34:716-718.
28. Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15:784-795.
29. Jacobs SC. Spread of prostatic cancer to bone. Urology. 1983;21:337-344.
30. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000;82:858-864.
31. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev. 2001;27:187-192.